How Novo Nordisk quietly changed the world of weight loss

For most of its hundred-year history, Novo Nordisk was the kind of company most people outside Denmark had never heard of. It made insulin. It made it quietly, consistently, and at a scale that mattered enormously to the people who depended on it and almost not at all to the wider cultural conversation. Headquartered in Bagsværd, a quiet suburb north of Copenhagen, it conducted its business in the calm, methodical Scandinavian way that does not generate headlines. For decades, that was the company. Insulin, diabetes, decency, very little drama.

And then, somewhere between 2017 and 2023, the same company that had spent a century perfecting a hormone for diabetes became the most talked-about pharmaceutical brand on earth. Its name began appearing in fashion magazines, in late-night monologues, in red-carpet whispers, in the corners of group chats where people compared notes on appetite and body image. Two of its products — Ozempic and Wegovy — entered the cultural vocabulary so completely that the molecule inside them, semaglutide, became a household word that most users could neither spell nor pronounce.

By the spring of 2023, Novo Nordisk had briefly become the most valuable publicly traded company in Europe. Its market capitalisation exceeded the entire annual GDP of the country it called home. A Danish insulin company, for the first time, was reshaping the global conversation about weight.

This is the long version of how that happened — and why the version most people have heard, the one about a miracle weight-loss drug invented overnight, misses almost everything that matters about it.

The quick answer

Danish roots: insulin in Copenhagen

The Novo Nordisk story begins, fittingly, with a marriage. In the early 1920s, after the discovery of insulin in Toronto, a Danish physician named August Krogh and his wife Marie — herself a doctor and a person with diabetes — secured the rights to produce insulin in Scandinavia. The first Danish insulin was made in their basement. Within a few years, two competing Danish companies had emerged from that early work: Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. Both made insulin. Both grew. Both spent most of the twentieth century as quiet, technically excellent, fiercely Danish manufacturers of one of the most important medicines of the modern era.

In 1989, after decades of parallel evolution and occasional rivalry, the two companies merged to become Novo Nordisk. By that point the combined entity was already among the world's largest producers of insulin, with operations in dozens of countries and a global reputation for diabetes care. The corporate culture that emerged from the merger was distinctly Scandinavian — long-horizon, research-heavy, modestly spoken, financially conservative. The company's largest shareholder, the Novo Nordisk Foundation, was and remains a non-profit, which gave the business a structural patience that publicly held competitors rarely had. Quarterly earnings mattered. Twenty-year research bets mattered more.

This is the under-told part of the story. The company that ended up changing global weight loss did not stumble into its success. It spent decades building the kind of scientific infrastructure that makes a discovery like semaglutide possible — and then it spent another two decades on the discovery itself.

From diabetes care to a quieter question about appetite

By the late twentieth century, Novo Nordisk had a problem that, viewed from outside, did not look like a problem. It dominated insulin. Insulin was a mature market. Growth was steady but not spectacular, and the company's executives understood that resting on a single hormone for another century was not a strategy. The question was where to go next.

Type 2 diabetes — the form of diabetes increasingly tied to weight, age, and the metabolic profile of modern life — was the obvious adjacency. The number of people with type 2 was rising every decade. Insulin helped, but it did not address the underlying picture. The scientific community was beginning to ask questions about the hormones that govern appetite, satiety, insulin release, and the broader regulation of metabolic health. Among those hormones was a relatively obscure gut peptide called glucagon-like peptide-1 — GLP-1.

GLP-1 had been identified in the 1980s. It was known to slow gastric emptying, stimulate insulin release in response to food, and reduce appetite. It was also known to have a useful clinical half-life of roughly two minutes, which meant it was, on its own, almost entirely useless as a medication. The challenge — and the project that Novo Nordisk's research division took on with unusual conviction in the 1990s — was to design a version of GLP-1 that the body could not break down so quickly. A molecule that would persist. A molecule that could be given as a weekly injection rather than a continuous infusion.

It took the better part of two decades.

The rise of semaglutide

The first commercial GLP-1 medication from Novo Nordisk was liraglutide, sold as Victoza for diabetes from 2009 and, in a higher dose, as Saxenda for weight management from 2014. Liraglutide worked. It produced meaningful improvements in blood sugar and modest, real weight loss. It was a daily injection, which limited adherence, and its weight-loss results, while clinically significant, were not the kind of numbers that capture a wider conversation.

Behind the scenes, the company's chemists had already moved on. They were working on a molecule with a longer fatty-acid side chain that bound to albumin in the blood, slowing its clearance and extending its half-life to roughly a week. They called it semaglutide. By the time the Phase 3 diabetes trials were completed in the mid-2010s, the data was unambiguous. Semaglutide lowered blood sugar more than its predecessors, and it produced weight loss that was substantially larger than anything the GLP-1 field had previously achieved.

In late 2017, the U.S. Food and Drug Administration approved semaglutide for type 2 diabetes under the brand name Ozempic. The launch was successful by pharmaceutical standards but unremarkable by cultural ones. Ozempic was, at that point, a diabetes drug. It came in an elegant pre-filled pen — Scandinavian design, blue and white, almost domestic in its restraint — and it was prescribed by endocrinologists for the management of a chronic disease. There was no celebrity story. There was no internet conversation. There was just a slightly better drug for a serious illness.

What happened next was not, strictly speaking, Novo Nordisk's plan.

The cultural explosion nobody scripted

Diabetes patients on Ozempic, especially those who had been overweight, began losing weight. Not modest weight. Real, visible, conversation-starting weight. Word spread, at first quietly, through the kinds of networks that drive everything else in modern American culture — Los Angeles, New York, the specific corners of social media where the wealthy and the famous discuss appearance with each other. Physicians began receiving requests for Ozempic from patients who did not have diabetes. Off-label prescribing — using a medication approved for one indication to treat another — became, suddenly, a meaningful part of the prescribing pattern.

By 2021, when Novo Nordisk received FDA approval for a higher-dose version of semaglutide marketed specifically for weight management under the name Wegovy, the cultural ground was already prepared. Within months, Wegovy was on backorder. Pharmacies could not keep it. Patients with diabetes who depended on Ozempic for blood sugar control began reporting that they could not fill their prescriptions because off-label demand was emptying the supply chain. Novo Nordisk's manufacturing capacity, sized for a market that had been growing predictably for decades, was instantly inadequate for the new reality.

The shortage became its own news story, which fed the demand, which deepened the shortage. The company's market capitalisation began climbing in a way that made financial journalists pay attention. By 2023, Novo Nordisk briefly overtook luxury group LVMH as the most valuable publicly traded company in Europe. A Danish insulin maker was now worth more than a French house that owned Dior, Louis Vuitton, and a meaningful share of the global luxury market. The cultural irony was not lost on anyone.

Wegovy and the 'Skinny Jab' era

By 2023, the medication had names the company had not given it. 'Skinny Jab' arrived first in the British tabloid press and then in the wider European conversation. 'Skinny Pen' followed as the elegant injector design became a status object in its own right. 'The Hollywood Shot' captured the moment in American celebrity media when nearly every visibly slimmed-down public figure was rumoured to be on it. 'The O Word' became the polite way to reference Ozempic in conversations that did not want to mention it directly.

None of these names were marketing. They were the wild language of a culture trying to absorb a development it had not anticipated. The medication had escaped the territory of medicine and entered the territory of fashion, gossip, identity, and the long-running conversation about thinness that had structured Western culture for half a century. The fact that the medication was, at its origin, a serious treatment for a serious metabolic disease became almost incidental to the wider narrative.

From Skinny Jabs to the O Word: how culture absorbed the GLP-1 era →

Celebrity culture and the Hollywood Shot

The celebrity layer of the story is, in many ways, the least interesting one — but it is also the layer that propelled the medication into mass awareness, and it deserves a careful word. Through 2022 and 2023, Hollywood became visibly thinner. Red-carpet bodies that had been one shape for years were suddenly another. The change was widespread enough that journalists began asking direct questions in interviews, and famous people, who are normally articulate about almost everything, became conspicuously evasive about this one.

By mid-2023, a number of public figures had acknowledged using semaglutide. Many more were rumoured to. The look that emerged — leaner faces, sharper jaws, a slight loss of the soft fullness that thirty-something faces normally carry — acquired its own nickname, 'Ozempic face,' and became a cultural shorthand for the medication's most visible side effect: the loss of facial fat that accompanies any rapid weight loss, regardless of the cause.

What followed was a conversation that the company itself almost never engaged in publicly. Novo Nordisk had not asked to become the centre of a celebrity story. It had asked to bring a useful medication to a population with a serious chronic disease. The cultural reframing happened around the medication, not because of any decision the company made. The result, viewed from Bagsværd, was a kind of profoundly Scandinavian discomfort with the way the conversation was unfolding.

What people actually mean by 'Ozempic face' →

Controversy, criticism, and the harder questions

No medication of this scale and cultural reach arrives without criticism, and the criticisms of Novo Nordisk and the GLP-1 era are worth taking seriously. The four most consequential are not the ones that generate the loudest headlines.

The first is supply. For meaningful periods between 2022 and 2024, patients with type 2 diabetes who depended on Ozempic for blood sugar control could not obtain their medication because off-label weight-loss demand had outstripped manufacturing capacity. Novo Nordisk poured billions into expanding production, but the rebuild took years. For the people caught in the gap — many of whom had been stable on Ozempic for years — the human cost was real, and the company's slow response invited fair criticism.

The second is affordability. The list price of Wegovy in the United States, at over a thousand dollars a month before insurance, placed it well outside the reach of most of the population that could clinically benefit from it. The medication's success became, by 2023, a vivid example of a broader pattern in modern American healthcare — a breakthrough that was widely advertised, widely desired, and widely unobtainable for anyone without elite insurance or significant disposable income. The conversation about access has only deepened as more GLP-1 products have entered the market.

The third is body image. The medication arrived into a culture that had spent decades trying, with mixed success, to detach the conversation about health from the conversation about thinness. The GLP-1 era reattached them, hard. The weight-positive and intuitive-eating movements found themselves in the strange position of arguing about the meaning of a medication that, for many users, actually worked — and the cultural negotiation between body acceptance and effective pharmacological weight loss is still very much in progress.

The fourth is hype. By 2023, GLP-1 medications were being discussed, in some corners of the internet, as a near-universal solution — to weight, to addiction, to compulsive behaviour, to a long list of conditions that the data did not yet support. Novo Nordisk's own marketing was careful, but the cultural conversation was not, and the gap between the actual evidence and the popular narrative created a kind of background pressure that the medication itself was never designed to bear.

Beyond weight loss: a quieter scientific story

Underneath the celebrity coverage, a more interesting scientific story has been emerging. GLP-1 receptors are not located only in the gut. They appear throughout the brain, in regions associated with appetite, reward, anxiety, and addiction. The early evidence — much of it still preliminary — suggests that GLP-1 medications may have applications well beyond weight and blood sugar, including in alcohol use disorder, substance use disorders, certain neurodegenerative conditions, and broader cardiovascular health.

Novo Nordisk's published trial data has already established meaningful reductions in major adverse cardiovascular events for users with established heart disease. Other trial data points to improvements in obstructive sleep apnea, kidney function in diabetic patients, and several other metabolic endpoints. Whatever the medication's cultural reputation has become, its medical reputation — within the actual research community — is that of a tool that turned out to do considerably more than its developers had originally hoped.

The 'food noise' conversation belongs in this section as well. The reduction in persistent mental preoccupation with food that many users report on a GLP-1 medication is one of the most striking and least expected effects of the class. It is also one of the most interesting from a scientific perspective, because it points to a mechanism — a quieting of reward signalling rather than simple appetite suppression — that may be relevant to a much wider set of human experiences than the original diabetes indication suggested.

What food noise actually is, and what it feels like when it goes quiet →

A Danish company, suddenly enormous

It is worth pausing, briefly, on the scale of what has happened. Novo Nordisk's market value at its 2023 peak exceeded the annual gross domestic product of Denmark. The company became, by some measures, the single most important driver of Danish economic growth, accounting for a meaningful share of national GDP expansion in 2023 and 2024. The Danish krone strengthened. The Danish stock market reorganised itself around a single company. The phrase 'Dutch disease,' originally coined for the distortions caused by a sudden natural-resource boom, began appearing in serious commentary about the Danish economy.

None of this was Novo Nordisk's stated ambition. The company's leadership, in its communications and in interviews, has been notably restrained about its own success — the same Scandinavian temperament that built it. The Novo Nordisk Foundation, the non-profit majority shareholder, has used its enlarged endowment to fund medical research, public health, and life-sciences infrastructure across Denmark and beyond. The capital is being recycled into the kind of long-horizon scientific work that produced semaglutide in the first place, which may be the most interesting financial story in modern European pharmaceuticals.

The competitive landscape has also changed. Eli Lilly's tirzepatide — marketed as Mounjaro for diabetes and Zepbound for weight loss — has emerged as a meaningful rival, with data suggesting it produces somewhat larger weight loss on average than semaglutide. Novo Nordisk's response, a next-generation medication called CagriSema combining semaglutide with cagrilintide, is in late-stage trials. The race is not over. The territory is no longer the company's alone. But the territory itself, the entire field of obesity and metabolic medicine, would not exist in its current form without the decades of work Novo Nordisk did to bring GLP-1 into the clinic.

Wegovy vs Mounjaro: how the two medications actually compare →

What this means for the people on the medication

For the individual user — the person who has been on Wegovy for six months, or Ozempic for two years, or who is considering starting next month — the corporate story is mostly background. The medication is the medication. The injection is the injection. The slow weekly process of noticing what changes in appetite, energy, sleep, mood, body composition, and the relationship with food is the same regardless of which company makes the pen.

But the corporate story matters in one specific way. It is a useful reminder that the medication came from somewhere. It was not a viral product. It was not a wellness brand. It was the result of a hundred years of patient scientific work by an unflashy company in a small Northern European country, supported by a non-profit foundation that valued research over quarterly returns. The medication that has reshaped so much of the modern conversation about weight is, in its origins, one of the more sober and serious products in the history of metabolic medicine.

Users sometimes find this context steadying. The medication is not a fashion. It is a piece of long-developed science that ended up, almost by accident, becoming a cultural object. The journey itself — what to expect, what to track, what to ignore — benefits from the same calm that produced the medication in the first place. As more people begin navigating life on GLP-1 medications, some choose to track appetite changes, symptoms, hydration, and weekly patterns using tools like Skinny Wingman. The point is not optimisation. It is the slow, honest noticing of a body that is, in many small ways, becoming different.

Final reflection

Novo Nordisk did not set out to change the global conversation about weight. It set out, a hundred years ago, to make insulin for people who would otherwise die without it. Everything that followed — the merger, the diabetes franchise, the long bet on GLP-1, the slow optimisation of semaglutide, the Ozempic launch, the cultural explosion, the Wegovy era, the controversies, the market capitalisation that briefly exceeded the GDP of its own country — was a series of patient, mostly quiet steps that added up to one of the most consequential pharmaceutical stories of the twenty-first century.

The medication is not a miracle. It is a useful, well-studied, carefully developed tool that helps a specific set of biological problems and creates a specific set of new ones. The cultural reception has been louder than the medication itself, in the way that cultural receptions almost always are. And underneath the noise, in laboratories in Bagsværd and Indianapolis and a dozen other cities, the next generation of medications is already in trials. The era is not finished. It has barely started.

What Novo Nordisk has done, in the end, is help reframe what was possible. The conversation about obesity has shifted from one largely about willpower to one increasingly about biology. The conversation about appetite has shifted from one mostly about discipline to one increasingly about hormones and reward systems and the parts of the body that operate beneath conscious choice. Whether those shifts will be remembered as a public-health breakthrough, a cultural distortion, or — most likely — both at once is a question for the historians of the next decade. The Danish company that started in a basement with insulin will, by then, be onto whatever comes next. It usually is.